Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth

Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics

“…These differences correspond with typical clinical presentations associated with each age group. [48][49][50] The type of SGA medication being used in treatment may be an important consideration of monitoring since each SGA differs in their pharmacokinetics and side effect profile. If children are more often treated with one type of SGA and adolescents another, this presents different profiles of cardiometabolic risk to each age group and as a result different priorities for metabolic monitoring.…”

High-Expenditure Pharmaceutical Use Among Children in Medicaid

“…Interventions implemented by states to strengthen oversight and limit prescribing of antipsychotics, such as instituting previous authorization processes 29 or telephone access for primary care providers to consult child psychiatrists, 30 may be contributing to recent reports of decreased rates of prescribing of antipsychotics in pediatric Medicaid enrollees. 31 Study limitations include those related to the use of claims data. Although prescription data from such sources are generally thought to be reliable and valid, 32 we cannot track actual use (as distinct from dispensing) of medications.…”

We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database

“…They are approved medications for bipolar mania in children and adolescents, for adolescent schizophrenia, and for behavioral disturbances (irritability and aggression) associated with autism and/or intellectual disabilities in children and adolescents (3). Risperidone and aripiprazole are frequently prescribed in these populations also as treatment of attention-deficit/hyperactivity disorder (ADHD), eating disorders, anxiety, and sleep disorders (4,5). Despite such a significant increase in SGA use in children and adolescents, reliable and comprehensive efficacy and safety information from specific clinical studies in pediatric patients are still relatively scant (4)(5)(6).…”

“…Risperidone and aripiprazole are frequently prescribed in these populations also as treatment of attention-deficit/hyperactivity disorder (ADHD), eating disorders, anxiety, and sleep disorders (4,5). Despite such a significant increase in SGA use in children and adolescents, reliable and comprehensive efficacy and safety information from specific clinical studies in pediatric patients are still relatively scant (4)(5)(6). The lack of information on efficacy and safety of these medications in pediatric settings indeed increases the exposure of this young population to unwarranted risks (7)(8)(9)(10).…”